MedSource provides support for complex clinical trials with expertise in complex therapeutic areas such as oncology, neurology, and rare diseases and complicated study designs from first- in- human dose escalation to adaptive designed registration studies. As a company that supports the most complex clinical trials, we know they aren’t called trials for nothing. At MedSource, we know how to pivot to the demands of even the most challenging trial and how to support the needs of our biotech customers with flexibility and transparency throughout the study life cycle.
MedSource is an award-winning clinical research organization (CRO) that delivers high-quality clinical trials through strong relationships with specialization in oncology, neurology and rare diseases. We have participated in over 700 clinical trials globally; more than 200 of them have been in oncology. Our efforts support biopharmaceutical clients who conduct complex clinical trials in the most challenging disease states and patient populations. Our wide experience encompasses a range of therapeutic areas, product types, clinical trial phases and study designs. Whether a challenging therapeutic area or a sophisticated trial design, our highly experienced team excels at delivering results.
See more About why MedSource takes relationships as seriously as science.
A Personalized Approach: unique strategies and data mining for small biotech companies
When getting a new compound into the clinic, companies need a well-researched strategy to navigate the clinical trial landscape successfully. However, many up-and-coming enterprises do not possess the resources required to navigate these incredibly complicated and competitive waters.
In the Face of Adversity: Flexible Clinical Trial Strategies for Small Biotech Companies
The landscape for clinical trials is a chaotic one. Given the cost and resources required, it’s vital for any company to do adequate research of competitors and existing products before even beginning its strategic plan.
Sophisticated Clinical Trials for Challenging Therapeutic Areas
At a time when clinical trials are becoming more and more complex – due in no small part to increased regulatory requirements – phase III trials are especially complicated, withfew drugs proceeding (approximately one-third) from phase II.
“One of the biggest things I respect about them is they admit when they can’t do something. They never offered to sell us a study they weren’t able to do or hadn’t done before, even though they could have. They only offer services that they know they have expertise in.”